Please login to the form below

Not currently logged in
Email:
Password:

PR company appoints new UK head

Chamberlain Healthcare Public Relations has appointed Mark John Cater as managing director of its London office

Chamberlain Healthcare Public Relations, an inVentiv Health company, has appointed Mark John Cater as managing director of its London office.

Prior to joining Chamberlain, Cater was regional director, Europe, Middle East, Africa and India for Cohn & Wolfe, and chief executive officer of GCI UK before the company merged in 2008 with Cohn & Wolfe. He also spent six years in various leadership roles as partner and director at public relations agency Ketchum, where he was responsible for the company's worldwide healthcare practice and served in both the London and New York offices.  

"Given our brief tenure but serious intentions in London, it is important we attract the best leadership," said Richard Chamberlain, the agency's president. "Mark's 22 years of public relations experience in both the public and private sectors across the UK, European and the US markets makes him exceptionally qualified to lead our London team, support our worldwide clients and further our global communications efforts." 

Chamberlain Healthcare Public Relations serves the healthcare sector exclusively. Operating in London since 2008, the firm works on behalf of several US-based, worldwide pharmaceutical clients on their global brands and issues.

 

4th January 2010

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rock Unlimited

Rock Unlimited: Science as you've never seen it...

Latest intelligence

UK life sciences minister George Freeman
Creating a 21st century life sciences ecosystem
The UK’s life sciences minister on how government and pharma can encourage NHS uptake and innovation...
Improving Corporate Memory as a Patient Safety Strategy
An article by Lorri Zipperer...
Online Physician Communities
How can pharma innovate in child and TYA cancer?
by Dr Tim Ringrose, M3 (EU)...